Inamed
This article was originally published in The Gray Sheet
Executive Summary
McGhan Medical subsidiary's round saline breast implants used for augmentation will cost 12% more as of Sept. 15, parent company Inamed says in an Aug. 7 release. The price hike is the first in five years and may affect third quarter financials depending on the reaction of customers and competitors, according to company President and CEO Ilan Reich. Recent speculation over breast implant price erosion has raised concern on Wall Street (1"The Gray Sheet" July 31, p. 7)